Nifty
:
14238.90
Sensex
:
48347.59
-133.00 (-0.93%)
-530.95 (-1.09%)
Nifty
Sensex
:
:
14238.90
48347.59
-133.00 (-0.93%)
-530.95 (-1.09%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
74/99

BSE: 533573 | NSE: APLLTD

NSE BSE
961.50
25-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  945.40
  •  979.00
  •  932.55
  •  939.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  952471
  •  9101.05
  •  1145.00
  •  434.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,879.89
  • 16.83
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,566.29
  • 1.04%
  • 4.13

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.78%
  • 0.41%
  • 11.18%
  • FII
  • DII
  • Others
  • 6.96%
  • 10.02%
  • 1.65%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.38
  • 7.79
  • 13.74

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.85
  • 3.85
  • 14.56

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.52
  • 2.85
  • 25.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.28
  • 19.57
  • 19.08

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.24
  • 5.02
  • 4.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.22
  • 13.93
  • 13.75

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
1,314.33
1,209.13
8.70%
1,457.10
1,240.87
17.43%
1,341.32
948.91
41.35%
1,206.83
926.95
30.19%
Expenses
949.24
884.08
7.37%
1,013.67
895.35
13.21%
933.96
724.00
29.00%
879.31
748.91
17.41%
EBITDA
365.09
325.05
12.32%
443.43
345.52
28.34%
407.36
224.91
81.12%
327.52
178.04
83.96%
EBIDTM
27.78%
26.88%
30.43%
27.84%
30.37%
23.70%
14.01%
14.01%
Other Income
2.53
0.41
517.07%
3.22
0.36
794.44%
0.32
3.29
-90.27%
0.89
3.37
-73.59%
Interest
2.31
7.36
-68.61%
4.48
7.07
-36.63%
6.67
4.98
33.94%
7.75
5.08
52.56%
Depreciation
46.97
41.82
12.31%
43.78
35.95
21.78%
41.50
35.40
17.23%
44.14
29.95
47.38%
PBT
318.34
276.28
15.22%
398.39
302.86
31.54%
359.51
155.03
131.90%
265.66
146.38
81.49%
Tax
59.14
48.60
21.69%
72.98
52.49
39.04%
66.77
35.96
85.68%
62.14
14.90
317.05%
PAT
259.20
227.68
13.84%
325.41
250.37
29.97%
292.74
119.07
145.86%
203.52
131.48
54.79%
PATM
19.72%
18.83%
22.33%
20.18%
21.82%
12.55%
7.11%
7.11%
EPS
14.89
12.42
19.89%
16.96
13.06
29.86%
15.55
6.34
145.27%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
5,319.58
4,605.76
3,934.69
3,130.18
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
22.97%
17.06%
25.70%
-0.14%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
5,586.81
1,039.38
992.71
885.56
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
-267.23
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
-5.02%
77.43%
74.77%
71.71%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
3,776.18
3,391.69
3,078.87
2,514.92
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
102.40
88.86
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
906.44
746.69
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
19.68%
18.98%
19.90%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
368.41
269.25
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
8.00%
6.84%
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
339.82
340.56
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
531.19
590.28
380.21
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
11.53%
15.00%
12.15%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
104.05
50.52
28.03
26.58
117.38
17.26
15.86
7.27
20.11
113.65
% Of Sales
-
2.26%
1.28%
0.90%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
1,543.40
1,214.07
855.82
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
29.01%
26.36%
21.75%
19.66%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
6.96
13.88
27.14
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
21.21
27.16
18.41
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
176.39
157.32
115.23
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
1,341.90
1,043.47
749.32
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
261.03
199.18
156.75
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
19.45%
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
1,080.87
828.76
593.65
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
1,095.95
800.64
592.57
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
15.08
28.12
1.08
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
20.32%
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
48.35%
39.60%
41.10%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
EPS
54.98
42.15
30.20
21.40
20.70
36.63
14.38
11.98
8.41
6.62
4.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,219.40
2,718.83
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
3,181.70
2,681.13
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
1,046.98
570.06
576.20
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
886.99
499.30
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
74.51
52.03
40.76
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,751.61
1,489.66
1,144.40
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
625.93
644.34
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
226.98
380.19
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
860.50
429.13
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
38.20
36.00
34.41
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
5,989.03
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
1,551.84
1,158.45
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
526.86
364.12
249.09
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
3,526.30
2,820.02
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
17.62
48.76
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
110.66
61.58
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
2,462.73
1,957.74
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,187.54
967.27
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
864.75
488.92
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
80.74
205.62
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
329.70
18.21
27.49
7.56
140.17
119.98
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
301.61
277.72
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
711.12
468.08
680.34
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
5,989.03
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
449.15
811.97
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
999.82
749.32
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
278.28
117.57
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
-592.84
111.56
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
685.26
978.45
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-236.11
-166.48
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-731.64
-755.60
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-789.71
-630.35
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-326.86
-215.85
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
384.93
90.60
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
154.85
59.03
502.63
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
-127.64
115.40
-69.33
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
199.07
83.74
153.07
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
71.84
199.07
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
170.79
144.24
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
14.87%
13.59%
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.52
2.85
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
53.64
47.09
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
85.38
78.91
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
69.87
88.23
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
69.15
37.76
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.54
0.42
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
37.81
41.70
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Alembic Pharmaceuticals gets USFDA’s nod for Midodrine Hydrochloride Tablets
    22nd Jan 2021, 11:46 AM

    The company has a cumulative total of 138 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals reports 25% rise in Q3 consolidated net profit
    19th Jan 2021, 16:20 PM

    Total income of the company increased by 8.87% at Rs 1316.86 crore for Q3FY21

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Asenapine Sublingual Tablets
    11th Dec 2020, 10:31 AM

    The company has a cumulative total of 137 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Metolazone Tablets
    3rd Dec 2020, 12:12 PM

    The company has a cumulative total of 137 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals’ arm gets nod for Investigational New Drug application
    2nd Dec 2020, 11:38 AM

    The initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020

    Read More
  • Alembic Pharmaceuticals’ JV gets tentative approval for Testosterone Gel
    25th Nov 2020, 11:46 AM

    The company has a cumulative total of 136 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Palbociclib Capsules
    9th Nov 2020, 10:37 AM

    Palbociclib Capsules, 75 mg, 100 mg, and 125 mg have an estimated market size of $624 million for twelve months ending Jun 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Timolol Maleate Ophthalmic Gel Forming Solution
    26th Oct 2020, 09:44 AM

    Alembic has a cumulative total of 134 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals reports 35% rise in Q2 consolidated net profit
    23rd Oct 2020, 11:41 AM

    Total income of the company increased by 17.65% at Rs 1460.32 crore for Q2FY21

    Read More
  • Alembic Pharma - Quarterly Results
    22nd Oct 2020, 16:16 PM

    Read More
  • Alembic Pharmaceuticals’ JV gets final approval for Tavaborole Topical Solution
    22nd Oct 2020, 11:38 AM

    Tavaborole Topical Solution, 5% has an estimated market size of $82 million for twelve months ending June 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Fenofibrate Capsules
    21st Oct 2020, 11:49 AM

    Alembic Pharmaceuticals has a cumulative total of 133 ANDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.